The trials produced promising results, showing that zolbetuximab can significantly extend the lives of patients with advanced gastric cancer. Based on the success of these trials, zolbetuximab has ...
After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer med ... containing chemotherapy. Patients must have the CLDN18.2 ...
Oct. 18, 2024 — Researchers have developed an in vitro cancer model to investigate why breast cancer spreads to bone. Their findings hold promise for advancing the development of preclinical ...